225 related articles for article (PubMed ID: 18375446)
21. Intra-arterial continuous infusion for treatment of pancreatic and biliary tract cancer.
Zanon C; Alabiso O; Grosso M; Buosi R; Chiappino I; Clara R; Satolli A; Zai S; Bortolini M; Botta M; Mussa A
Int J Pancreatol; 2000 Jun; 27(3):225-33. PubMed ID: 10952405
[TBL] [Abstract][Full Text] [Related]
22. Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors.
Rachamalla R; Malamud S; Grossbard ML; Mathew S; Dietrich M; Kozuch P
Anticancer Drugs; 2004 Mar; 15(3):211-7. PubMed ID: 15014353
[TBL] [Abstract][Full Text] [Related]
23. A phase II trial of gemcitabine and weekly high-dose 5-fluorouracil in a 48-hour continuous-infusion schedule in patients with advanced pancreatic carcinoma. A study of the Spanish Cooperative Group for Gastrointestinal Tumour Therapy (TTD).
Santasusana JM; García López JL; García JJ; Carbonero AI; Plazas JG; Rovira PS; Martos CF; Guzmán MC; Jericó JF; Delgado FJ; Espinosa JC; Muñoz ML; Aguilar EA; Valera JS; García Ribas I; Mena AC
Clin Transl Oncol; 2005 Dec; 7(11):493-8. PubMed ID: 16373060
[TBL] [Abstract][Full Text] [Related]
24. Gemcitabine-capecitabine plus intra-arterial epirubicin-cisplatin in pretreated pancreatic cancer patients: a phase I study.
Mambrini A; Pacetti P; Del Freo A; Seta RD; Pezzuolo D; Torri T; Orlandi M; Tartarini R; Cantore M
Anticancer Res; 2009 May; 29(5):1547-9. PubMed ID: 19443364
[TBL] [Abstract][Full Text] [Related]
25. Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer.
Goel A; Grossbard ML; Malamud S; Homel P; Dietrich M; Rodriguez T; Mirzoyev T; Kozuch P
Anticancer Drugs; 2007 Mar; 18(3):263-71. PubMed ID: 17264757
[TBL] [Abstract][Full Text] [Related]
26. Clinical efficacy of intra-arterial pharmacokinetic chemotherapy with 5-fluorouracil, CDDP, gemcitabine, and angiotensin-II in patients with advanced pancreatic cancer.
Ishikawa T; Kamimura H; Tsuchiya A; Togashi T; Watanabe K; Seki K; Ohta H; Yoshida T; Takeda K; Kamimura T
Hepatogastroenterology; 2007 Dec; 54(80):2378-82. PubMed ID: 18265669
[TBL] [Abstract][Full Text] [Related]
27. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.
Berlin JD; Catalano P; Thomas JP; Kugler JW; Haller DG; Benson AB
J Clin Oncol; 2002 Aug; 20(15):3270-5. PubMed ID: 12149301
[TBL] [Abstract][Full Text] [Related]
28. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial.
Reni M; Cordio S; Milandri C; Passoni P; Bonetto E; Oliani C; Luppi G; Nicoletti R; Galli L; Bordonaro R; Passardi A; Zerbi A; Balzano G; Aldrighetti L; Staudacher C; Villa E; Di Carlo V
Lancet Oncol; 2005 Jun; 6(6):369-76. PubMed ID: 15925814
[TBL] [Abstract][Full Text] [Related]
29. Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer.
Lee S; Oh SY; Kim BG; Kwon HC; Kim SH; Rho MH; Kim YH; Rho MS; Jeong JS; Kim HJ
Am J Clin Oncol; 2009 Aug; 32(4):348-52. PubMed ID: 19363436
[TBL] [Abstract][Full Text] [Related]
30. Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.
Starling N; Watkins D; Cunningham D; Thomas J; Webb J; Brown G; Thomas K; Oates J; Chau I
J Clin Oncol; 2009 Nov; 27(33):5499-505. PubMed ID: 19858399
[TBL] [Abstract][Full Text] [Related]
31. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
[TBL] [Abstract][Full Text] [Related]
32. A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers.
Davis EJ; Griffith KA; Kim EJ; Ruch JM; McDonnell KJ; Zalupski MM
Am J Clin Oncol; 2018 Feb; 41(2):128-132. PubMed ID: 26535993
[TBL] [Abstract][Full Text] [Related]
33. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
[TBL] [Abstract][Full Text] [Related]
34. Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM).
Louvet C; André T; Hammel P; Selle F; Landi B; Cattan S; Fonck M; Flesch M; Colin P; Balosso J; Ruszniewski P; de Gramont A
Ann Oncol; 2001 May; 12(5):675-9. PubMed ID: 11432627
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.
Neoptolemos JP; Stocken DD; Bassi C; Ghaneh P; Cunningham D; Goldstein D; Padbury R; Moore MJ; Gallinger S; Mariette C; Wente MN; Izbicki JR; Friess H; Lerch MM; Dervenis C; Oláh A; Butturini G; Doi R; Lind PA; Smith D; Valle JW; Palmer DH; Buckels JA; Thompson J; McKay CJ; Rawcliffe CL; Büchler MW;
JAMA; 2010 Sep; 304(10):1073-81. PubMed ID: 20823433
[TBL] [Abstract][Full Text] [Related]
36. A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer: an Eastern Cooperative Oncology Group Study (E3296).
Berlin JD; Adak S; Vaughn DJ; Flinker D; Blaszkowsky L; Harris JE; Benson IIIAB
Oncology; 2000 Apr; 58(3):215-8. PubMed ID: 10765123
[TBL] [Abstract][Full Text] [Related]
37. Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer.
Shiah HS; Cheng AL; Hsu C; Hsu CH; Liu TW; Chang JY; Jan CM; Chao Y; Yu WL; Chuang TR; Whang-Peng J; Chen LT
J Gastroenterol Hepatol; 2006 Mar; 21(3):531-6. PubMed ID: 16638094
[TBL] [Abstract][Full Text] [Related]
38. Advanced pancreatic carcinoma showing a complete response to arterial infusion chemotherapy.
Homma H; Akiyama T; Mezawa S; Doi T; Takanashi K; Machida T; Murakami K; Katsuki S; Sato T; Hirata K
Int J Clin Oncol; 2004 Jun; 9(3):197-201. PubMed ID: 15221606
[TBL] [Abstract][Full Text] [Related]
39. Gemcitabine and protracted 5-FU for advanced pancreatic cancer. A phase II study.
Kurtz JE; Kohser F; Négrier S; Trillet-Lenoir V; Walter S; Limacher JM; Untereiner M; Kayitalire L; Jaeck D; Dufour P
Hepatogastroenterology; 2000; 47(35):1450-3. PubMed ID: 11100374
[TBL] [Abstract][Full Text] [Related]
40. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.
Poplin E; Feng Y; Berlin J; Rothenberg ML; Hochster H; Mitchell E; Alberts S; O'Dwyer P; Haller D; Catalano P; Cella D; Benson AB
J Clin Oncol; 2009 Aug; 27(23):3778-85. PubMed ID: 19581537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
